Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy

Wakaba Yamaguchi; Naofumi Yui; Toshikage Nagao; Gaku Oshikawa; Mariko Negi; Soichiro Iimori; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida

doi:10.2169/internalmedicine.55.5310

CASE REPORTS

Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy

Wakaba Yamaguchi, Naofumi Yui, Toshikage Nagao, Gaku Oshikawa, Mariko Negi, Soichiro Iimori, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida

Author information

Wakaba Yamaguchi
Department of Nephrology, Tokyo Medical and Dental University, Japan
Naofumi Yui
Department of Nephrology, Tokyo Medical and Dental University, Japan
Toshikage Nagao
Department of Hematology, Tokyo Medical and Dental University, Japan
Gaku Oshikawa
Department of Hematology, Tokyo Medical and Dental University, Japan
Mariko Negi
Department of Pathology, Tokyo Medical and Dental University, Japan
Soichiro Iimori
Department of Nephrology, Tokyo Medical and Dental University, Japan
Tomokazu Okado
Department of Nephrology, Tokyo Medical and Dental University, Japan
Tatemitsu Rai
Department of Nephrology, Tokyo Medical and Dental University, Japan
Shinichi Uchida
Department of Nephrology, Tokyo Medical and Dental University, Japan

Keywords: multiple myeloma, maintenance therapy, bortezomib, hemodialysis, fibrosis, myofibroblast

JOURNAL OPEN ACCESS

2016 Volume 55 Issue 3 Pages 263-268

DOI https://doi.org/10.2169/internalmedicine.55.5310

Details

Abstract

The effectiveness of bortezomib treatment for multiple myeloma (MM) is well established. However, the protocol by which maintenance therapy using bortezomib should be continued for myeloma patients requiring regular hemodialysis remains to be established. We herein report a case of MM with severe renal insufficiency requiring hemodialysis for nearly 30 months which was finally withdrawn from renal replacement therapy during monthly maintenance treatment with bortezomib and dexamethasone for two years. The details of this case are essential for establishing clinical guidelines for applying intermittent low-frequency bortezomib therapy in dialysis-dependent myeloma patients.

Corresponding author

Register with J-STAGE for free!